… cisplatin plus gemcitabine. In that study of 27 assessable patients with advanced or metastatic
non–small-cell lung cancer (… of gemcitabine plus cisplatin compared with cisplatin alone in …

… gemcitabine-cisplatin with etoposide-cisplatin in the treatment of patients with advanced
non–small-cell lung cancer (… were randomized to receive either gemcitabine 1,250 mg/m 2 …

… day-8 dose of gemcitabine because of bone marrow … cisplatin 80 mg/m 2 , gemcitabine
1000 mg/m 2 or cisplatin 60 mg/m 2 , gemcitabine 1000 mg/m 2 ; carboplatin AUC 5, gemcitabine …

… IV NSCLC received gemcitabine 1250 mg/m 2 (days 1 and 8) plus cisplatin 80 mg… gemcitabine
plus cisplatin therapy were randomized (2:1 fashion) to receive maintenance gemcitabine …

… , and the toxicity of gemcitabine/cisplatin (GP) and gemcitabine/… lung cancer (NSCLC).
Methods: Patients were randomized to GP (gemcitabine 1200 mg/m 2 , days 1 and 8 plus cisplatin …

… and toxicity of gemcitabine (GEM) versus the combination of cisplatin and etoposide (EP)
in Chinese patients with inoperable (stage III or IV) non-small-cell lung cancer (NSCLC). …

… in non-small cell lung cancer (NSCLC). The Spanish Lung Cancer Group (SLCG) therefore
… of higher doses than usual of gemcitabine along with cisplatin in patients with advanced …

… advanced non-small-cell lung cancer (NSCLC) is extremely poor. … of gemcitabine and cisplatin
in advanced NSCLC. … % of both the cisplatin and gemcitabine dosages in the subsequent …

… phase II study, the cisplatin, gemcitabine, and vinorelbine (… advanced non–small-cell lung
cancer (NSCLC) patients. The … cisplatin and vinorelbine (PV) or cisplatin and gemcitabine (PG…

… gemcitabine 24 in patients with advanced NSCLC. We therefore hypothesized that the addition
of sorafenib to gemcitabine/cisplatin … and safety of sorafenib plus gemcitabine/cisplatin in …